The landscape and therapeutic relevance of cancer-associated transcript fusions

Oncogene

Volumn 34, Issue 37, 2015, Pages 4845-4854

  Yoshihara, K ^a,b   Wang, Q ^a   Torres Garcia, W ^a   Zheng, S ^a   Vegesna, R ^a   Kim, H ^a   Verhaak, R G W ^a,b  

^a UNIVERSITY OF TEXAS   (United States)

^b NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; ESTROGEN RECEPTOR ALPHA; FIBROBLAST GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR RECEPTOR 3; HISTONE DEMETHYLASE; HISTONE METHYLTRANSFERASE; PROTEIN KINASE; PROTEIN RET; RECEPTOR TYROSINE KINASE LIKE ORPHAN RECEPTOR; MESSENGER RNA; ONCOPROTEIN; RNA;

ACUTE MYELOBLASTIC LEUKEMIA; ARTICLE; BLADDER CARCINOMA; BREAST CANCER; CARCINOGENESIS; COPY NUMBER VARIATION; CUTANEOUS MELANOMA; CYSTADENOCARCINOMA; FUSION GENE; GENE DOSAGE; GENE FREQUENCY; GENE IDENTIFICATION; GENE MUTATION; GENE REARRANGEMENT; GENETIC TRANSCRIPTION; GENOMIC INSTABILITY; GLIOBLASTOMA; GLIOMA; HEAD AND NECK CANCER; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; KIDNEY CARCINOMA; LUNG ADENOCARCINOMA; MULTIGENE FAMILY; PRIMARY TUMOR; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; RNA SEQUENCE; SQUAMOUS CELL LUNG CARCINOMA; THYROID CARCINOMA; TRANSCRIPT FUSION; TRANSITIONAL CELL CARCINOMA; BIOLOGY; CELL TRANSFORMATION; CHROMATIN ASSEMBLY AND DISASSEMBLY; CLASSIFICATION; DNA MUTATIONAL ANALYSIS; GENE EXPRESSION PROFILING; GENETIC HETEROGENEITY; GENETICS; MOLECULARLY TARGETED THERAPY; NEOPLASMS; PROCEDURES; SEQUENCE ALIGNMENT;

CELL TRANSFORMATION, NEOPLASTIC; CHROMATIN ASSEMBLY AND DISASSEMBLY; COMPUTATIONAL BIOLOGY; DNA MUTATIONAL ANALYSIS; GENE EXPRESSION PROFILING; GENETIC HETEROGENEITY; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; ONCOGENE PROTEINS, FUSION; RNA, MESSENGER; RNA, NEOPLASM; SEQUENCE ALIGNMENT;

EID: 84929852263     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2014.406     Document Type: Article

References (53)

1. Mitelman F, Johansson B, Mertens F. The impact of translocations and gene fusions on cancer causation. Nat Rev Cancer 2007; 7: 233-245.
2. Nowell PC, Hungerford DA. A minute chromosome in human chronic granulocytic leukemia. Science 1960; 132: 1488-1501.
3. Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010; 362: 2260-2270.
4. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S et al. IDentification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007; 448: 561-566.
5. Shaw AT, Kim DW, Nakagawa K, Seto T, Crino L, Ahn MJ et al. Crizotinib versus chemotherapy in adVanced ALK-positive lung cancer. N Engl J Med 2013; 368: 2385-2394.
6. Meyerson M, Gabriel S, Getz G. AdVances in unDerstanding cancer genomes through second-generation sequencing. Nat Rev Genet 2010; 11: 685-696.
7. Watson IR, Takahashi K, Futreal PA, Chin L. Emerging patterns of somatic mutations in cancer. Nat Rev Genet 2013; 14: 703-718.
8. Singh D, Chan JM, Zoppoli P, Niola F, SulliVan R, Castano A et al. Transforming fusions of FGFR and TACC genes in human glioblastoma. Science 2012; 337: 1231-1235.
9. Guo G, Sun X, Chen C, Wu S, Huang P, Li Z et al. Whole-genome and whole-exome sequencing of bladDer cancer iDentifies frequent alterations in genes involved in sister chromatid cohesion and segregation. Nat Genet 2013; 45: 1459-1463.
10. Wu YM, Su F, Kalyana-Sundaram S, Khazanov N, Ateeq B, Cao X et al. IDentification of targetable FGFR gene fusions in diverse cancers. Cancer Discov 2013; 3: 636-647.
11. Parker M, Mohankumar KM, Punchihewa C, Weinlich R, Dalton JD, Li Y et al. C11orf95-RELA fusions drive oncogenic NF-kappaB signalling in ependymoma. Nature 2014; 506: 451-455.
12. Honeyman JN, Simon EP, Robine N, Chiaroni-Clarke R, Darcy DG, Lim II et al. Detection of a recurrent DNAJB1-PRKACA chimeric transcript in fibrolamellar hepatocellular carcinoma. Science 2014; 343: 1010-1014.
13. Shah N, Lankerovich M, Lee H, Yoon JG, SchroeDer B, Foltz G. Exploration of the gene fusion landscape of glioblastoma using transcriptome sequencing and copy number data. BMC Genomics 2013; 14: 818.
14. Shern JF, Chen L, Chmielecki J, Wei JS, Patidar R, Rosenberg M et al. Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusionnegative tumors. Cancer Discov 2014; 4: 216-231.
15. Seo JS, Ju YS, Lee WC, Shin JY, Lee JK, Bleazard T et al. The transcriptional landscape and mutational profile of lung aDenocarcinoma. Genome Res 2012; 22: 2109-2119.
16. Wu C, Wyatt AW, Lapuk AV, McPherson A, McConeghy BJ, Bell RH et al. Integrated genome and transcriptome sequencing iDentifies a novel form of hybrid and aggressive prostate cancer. J Pathol 2012; 227: 53-61.
17. Torres-Garcia W, Zheng S, Sivachenko A, Vegesna R, Wang Q, Yao R et al. PRADA: Pipeline for RNA sequencing Data Analysis. Bioinformatics 2014; 30: 2224-2226.
18. Chen K, Wallis JW, McLellan MD, Larson DE, Kalicki JM, Pohl CS et al. BreakDancer: an algorithm for high-resolution mapping of genomic structural variation. Nat Methods 2009; 6: 677-681.
19. Zack TI, Schumacher SE, Carter SL, Cherniack AD, Saksena G, Tabak B et al. Pancancer patterns of somatic copy number alteration. Nat Genet 2013; 45: 1134-1140.
20. Kalyana-Sundaram S, Shankar S, Deroo S, Iyer MK, Palanisamy N, Chinnaiyan AM et al. Gene fusions associated with recurrent amplicons represent a class of passenger aberrations in breast cancer. Neoplasia 2012; 14: 702-708.
21. Edgren H, Murumagi A, Kangaspeska S, Nicorici D, Hongisto V, Kleivi K et al. IDentification of fusion genes in breast cancer by paired-end RNA-sequencing. Genome Biol 2011; 12: R6.
22. Kim P, Yoon S, Kim N, Lee S, Ko M, Lee H et al. ChimerDB 2.0-a knowledgebase for fusion genes updated. Nucleic Acids Res 2010; 38: D81-D85.
23. Mitelman F, Johansson B, Mertens F. Fusion genes and rearranged genes as a linear function of chromosome aberrations in cancer. Nat Genet 2004; 36: 331-334.
24. Tomlins SA, RhoDes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005; 310: 644-648.
25. The Cancer Genome Atlas Research N, Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia. N Engl J Med 2013; 368: 2059-2074.
26. Zheng S, Fu J, Vegesna R, Mao Y, Heathcock LE, Torres-Garcia W et al. A survey of intragenic breakpoints in glioblastoma iDentifies a distinct subset associated with poor survival. Genes Dev 2013; 27: 1462-1472.
27. Brennan CW, Verhaak RG, McKenna A, Campos B, Noushmehr H, Salama SR et al. The somatic genomic landscape of glioblastoma. Cell 2013; 155: 462-477.
28. Shaw AT, Hsu PP, Awad MM, Engelman JA. Tyrosine kinase gene rearrangements in epithelial malignancies. Nat Rev Cancer 2013; 13: 772-787.
29. Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012; 367: 1694-1703.
30. Vaishnavi A, Capelletti M, Le AT, Kako S, Butaney M, Ercan D et al. Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer. Nat Med 2013; 19: 1469-1472.
31. Wells SA Jr, Gosnell JE, Gagel RF, Moley J, Pfister D, Sosa JA et al. VanDetanib for the treatment of patients with locally adVanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol 2010; 28: 767-772.
32. Lam ET, Ringel MD, Kloos RT, Prior TW, Knopp MV, Liang J et al. Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. J Clin Oncol 2010; 28: 2323-2330.
33. Hallberg B, Palmer RH. Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology. Nat Rev Cancer 2013; 13: 685-700.
34. Hojfeldt JW, Agger K, Helin K. Histone lysine Demethylases as targets for anticancer therapy. Nat Rev Drug Discov 2013; 12: 917-930.
35. Arrowsmith CH, Bountra C, Fish PV, Lee K, Schapira M. Epigenetic protein families: a new frontier for drug discovery. Nat Rev Drug Discov 2012; 11: 384-400.
36. Kantarjian H, Issa JP, Rosenfeld CS, Bennett JM, Albitar M, DiPersio J et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 2006; 106: 1794-1803.
37. Olsen EA, Kim YH, Kuzel TM, Pacheco TR, Foss FM, Parker S et al. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol 2007; 25: 3109-3115.
38. Daigle SR, Olhava EJ, Therkelsen CA, Majer CR, Sneeringer CJ, Song J et al. Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell 2011; 20: 53-65.
39. Teng YC, Lee CF, Li YS, Chen YR, Hsiao PW, Chan MY et al. Histone Demethylase RBP2 promotes lung tumorigenesis and cancer metastasis. Cancer Res 2013; 73: 4711-4721.
40. Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K, Sivachenko A et al. Mutational heterogeneity in cancer and the search for new cancerassociated genes. Nature 2013; 499: 214-218.
41. Asmann YW, Hossain A, Necela BM, Middha S, Kalari KR, Sun Z et al. A novel bioinformatics pipeline for iDentification and characterization of fusion transcripts in breast cancer and normal cell lines. Nucleic Acids Res 2011; 39: e100.
42. Gough SM, Lee F, Yang F, Walker RL, Zhu YJ, Pineda M et al. NUP98-PHF23 is a chromatin modifying oncoprotein that causes a wiDe array of leukemias sensitive to inhibition of PHD domain histone reaDer function. Cancer Discov 2014; 4: 564-577.
43. Cadot B, Brunetti M, Coppari S, FeDeli S, De Rinaldis E, Dello Russo C et al. Loss of histone Deacetylase 4 causes segregation Defects during mitosis of p53-Deficient human tumor cells. Cancer Res 2009; 69: 6074-6082.
44. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 2001; 98: 5116-5121.
45. Li H, Durbin R. Fast and accurate long-read alignment with Burrows-Wheeler transform. Bioinformatics 2010; 26: 589-595.
46. McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res 2010; 20: 1297-1303.
47. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N et al. The Sequence Alignment/Map format and SAMtools. Bioinformatics 2009; 25: 2078-2079.
48. Cancer Genome Atlas Research N, Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 2013; 499: 43-49.
49. Zhao M, Sun J, Zhao Z. TSGene: a web resource for tumor suppressor genes. Nucleic Acids Res 2013; 41: D970-D976.
50. Futreal PA, Coin L, Marshall M, Down T, Hubbard T, Wooster R et al. A census of human cancer genes. Nat Rev Cancer 2004; 4: 177-183.
51. Mermel CH, Schumacher SE, Hill B, Meyerson ML, Beroukhim R, Getz G. GISTIC2.0 facilitates sensitive and confiDent localization of the targets of focal somatic copynumber alteration in human cancers. Genome Biol 2011; 12: R41.
52. Li J, Lu Y, Akbani R, Ju Z, Roebuck PL, Liu W et al. TCPA: a resource for cancer functional proteomics data. Nat Methods 2013; 10: 1046-1047.
53. R Core Team R: A language and environment for statistical computing 2013.